Thyroxine and tri-iodothyronine are essential for normal organ function, growth, and development. Thyroxine and tri-iodothyronine regulate the basal metabolic rate, which includes hepatocytes, thereby modulating liver function. The liver plays a vital role in the metabolism of thyroid hormones and the peripheral conversion of thyroxine to triiodothyronine by type 1 deiodinase. To date, some previous studies have shown that the most common change in the plasma level of thyroid hormones is a reduction in the total T3 and free T3 concentration associated with the severity of hepatic dysfunction. The current study aims to evaluate thyroid function in patients with acute and chronic liver diseases. Objectives of the study include assessing the severity of liver dysfunction in patients with hypothyroidism and hyperthyroidism. This prospective, hospital-based cross-sectional study was conducted in the inpatient department of General medicine from October 2019 to October 2021. A comprehensive physical examination was conducted, followed by a thorough review of their hospital records. Patients with acute hepatitis (acute onset of jaundice and three-fold rise in serum transaminases) and chronic liver disease (evidence of liver disease of more than 6 months’ duration and portal hypertension on ultrasonography or upper gastrointestinal endoscopy) were included in the study. Results showed a significant positive correlation between TSH and prothrombin time, child-pugh score, and total bilirubin. Total T3, free T3, and free T4 showed a significant positive correlation with albumin and a significant negative correlation with prothrombin time, child-pugh score, and total and direct bilirubin. So, thyroid hormone patterns may help assess the prognosis of patients with liver disorders as they show a significant correlation with established markers of prognosis of liver diseases.

Reference

1.          Sorvillo F, Mazziotti G, Carbone A, Morisco F, Cioffi M, Rotondi M et al. Increased serum reverse triiodothyronine levels at diagnosis of hepatocellular carcinoma in patients with compensated HCV-related liver cirrhosis. Clin Endocrinol (Oxf). 2003 Feb;58(2):207-12. doi: 10.1046/j.1365-2265.2003.01697.x, PMID 12580937.

2.          Bebars GM, Sayed MA, Hamdy L, Abdel Aziz RA. Effect of acute and chronic liver diseases on the thyroid function in children. BMC Pediatr. 2021;21(1):361. doi: 10.1186/s12887-021-02816-8, PMID 34433432.

3.          Kayacetin E, Kisakol G, Kaya A. Low serum total thyroxine and free triiodothyronine in patients with hepatic encephalopathy due to non-alcoholic cirrhosis. Swiss Med Wkly. 2003 Apr 5;133(13-14):210-3. doi: 10.4414/smw.2003.10172, PMID 12811678.

4.          Zhang Y, Li J, Liu H. Correlation between the thyroid hormone levels and nonalcoholic fatty liver disease in type 2 diabetic patients with normal thyroid function. BMC Endocr Disord. 2022;22(1):144. doi: 10.1186/s12902-022-01050-2, PMID 35641932.

5.          Maheshwari A, Thuluvath PJ. Endocrine diseases and the liver. Clin Liver Dis. 2011;15(1):55-67. doi: 10.1016/j.cld.2010.09.008, PMID 21111993.

6.          Zietz B, Lock G, Plach B, Drobnik W, Grossmann J, Schölmerich J et al. Dysfunction of the hypothalamic-pituitary-glandular axes and relation to Child-Pugh classification in male patients with alcoholic and virus-related cirrhosis. Eur J Gastroenterol Hepatol. 2003 May;15(5):495-501. doi: 10.1097/01.meg.0000059115.41030.e0. PMID 12702906.

7.          Evans RM. The steroid and thyroid hormone receptor superfamily. Science. 1988;240(4854):889-95. doi: 10.1126/science.3283939, PMID 3283939.

8.          Li J, Bai L, Wei F, Wei M, Xiao Y, Yan W, et al. Effect of addition of thyroxine in the treatment of Graves’ disease: A systematic review. Front Endocrinol (Lausanne). 2020;11:560157. doi: 10.3389/fendo.2020.560157, PMID 33569041.

9.          Hassi J, Sikkilä K, Ruokonen A, Leppäluoto J. The pituitary-thyroid axis in healthy men living under subarctic climatological conditions. J Endocrinol. 2001;169(1):195-203. doi: 10.1677/joe.0.1690195, PMID 11250661.

10.        Sanders JP, Van der Geyten S, Kaptein E, Darras VM, Kühn ER, Leonard JL et al. Characterization of a propylthiouracil-insensitive type I iodothyronine deiodinase. Endocrinology. 1997;138(12):5153-60. doi: 10.1210/endo.138.12.5581, PMID 9389495.

11.        Leonard DM, Stachelek SJ, Safran M, Farwell AP, Kowalik TF, Leonard JL. Cloning, expression, and functional characterization of the substrate binding subunit of rat type II iodothyronine 59-deiodinase. J Biol Chem. 2000;275(33):25194-201. doi: 10.1074/jbc.M002036200, PMID 10829019.

12.        Tu HM, Legradi G, Bartha T, Salvatore D, Lechan RM, Larsen PR. Regional expression of the type 3 iodothyronine deiodinase messenger ribonucleic acid in the rat central nervous system and its regulation by thyroid hormone. Endocrinology. 1999;140(2):784-90. doi: 10.1210/endo.140.2.6486, PMID 9927306.

13.        Bianco AC, Salvatore D, Gereben B, Berry MJ, Larsen PR. Biochemistry, cellular and molecular biology, and physiological roles of the iodothyronine selenodeiodinases. Endocr Rev. 2002;23(1):38-89. doi: 10.1210/edrv.23.1.0455, PMID 11844744.